TRPM3 Antagonist Derivatives for Potency and Lower Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a significant medical need for novel, alternative, and/or better therapeutics for TRPM3 mediated disorders such as pain and epilepsy, particularly inflammatory pain and epileptic encephalopathies, with a focus on compounds that have good potency, low side-effects, and favorable pharmacokinetic or -dynamic properties.
Innovation Solution
Development of a class of novel compounds that act as TRPM3 antagonists, including specific derivatives of benzothiophene carboxylates, which can be used as modulators to treat TRPM3 mediated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing TRPM3 antagonists are used, then some therapeutic effect is achieved, but they have insufficient potency or high side-effects
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical structures of TRPM3 antagonist compounds. Specific substitutions at defined positions (R1, R2, R3, R4, R5, R6, R7, R8) with various functional groups (fluorine, chlorine, cyano, alkoxy, amino, etc.) optimize the balance between therapeutic potency and side effect profile, achieving improved reliability while reducing harmful effects.
Solution Approach 2:
The patent employs composite material principles by creating complex multi-substituted benzothiophene carboxylate structures. These compounds combine multiple functional groups and substituents in specific configurations to achieve synergistic effects that enhance therapeutic efficacy while minimizing side effects, representing a composite molecular architecture approach.
2Reliability
If existing TRPM3 antagonists are used, then some therapeutic effect is achieved, but they have poor pharmacokinetic properties
Solution Approach 1:
The patent optimizes pharmacokinetic properties through parameter changes in molecular structure. By adjusting substituent types, positions, and configurations (R1-R8 groups), the compounds achieve improved absorption, distribution, metabolism, and excretion profiles while maintaining therapeutic efficacy, resolving the contradiction between effectiveness and pharmacokinetic performance.
3Reliability
If novel TRPM3 antagonist compounds are developed, then therapeutic benefits are improved, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex molecule into defined structural modules with specific substitutable positions (R1, R2, R3, R4, R5, R6, R7, R8). This modular approach allows systematic optimization of therapeutic benefits while managing complexity through standardized substitution patterns and functional group selections at each position.
Solution Approach 2:
The patent manages compound complexity through controlled parameter changes by selecting from defined sets of substituents at each position. This systematic approach to structural variation enables optimization of therapeutic benefits while maintaining manageable complexity through standardized chemical modifications rather than entirely novel complex structures.
Data Source
AI summary
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain, epilepsy and inflammatory hypersensitivity. The invention also relates to a method for the prevention or treatment of said TRPM3 mediated disorders.